Electro-acupuncture for Irritable Bowel Syndrome With Constipation: a Pilot, Randomized, Double-blinded, Sham-controlled Trial

简要总结

详细描述

I) Study period: 14 weeks, including 2 weeks of run-in (wash-out), 6 weeks of treatment, and 6 weeks of follow-up. 15 visits will be scheduled for each participant, comprising 2 visits during recruitment and the wash-out period, 12 visits during the treatment period, and 1 visit at the end of the follow-up period. II) Coding of data: The trial uses patient-blind technique, which means needles for acupuncture and sham acupuncture will be of identical looking and use same package, conduct blinding according to randomization codes. The study will only be unblinded at final statistical analysis and in final report. In case of emergency code breaking, before code breaking, the investigator should well inform the principal investigator of the corresponding participating site. Investigators who break the codes need to explain the reasons and document on patients' notes. The following circumstances can be considered for an emergency breaking, including, but not limited to: (1) When a SAE happens and is considered to be relevant to experimental medication or placebo; (2) When a serious complication happens. III) AE/SAE reporting: All AEs that not meeting the criteria for SAEs will be captured on the case report form (CRF). The details include, but not be limited to: (1) date, (2) event description, (3) time of onset, (4) assessment of severity, (5) relationship to study intervention, and (6) time of resolution/stabilization of the event. All AEs occurring while on study will be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution or stabilization. Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. However, if the study participant's condition deteriorates at any time during the study, it will be recorded as an AE. Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each episode. Regarding SAEs, the study investigator will immediately report to the principal investigator for any SAE. SAEs will be followed until satisfactory resolution or until the investigator deems the event to be chronic or the participant is stable. Other supporting documentation of the event may be requested by the Research Ethics Committee (REC) and should be provided as soon as possible. All SAE must be evaluated by the principal investigator and investigators. Once it happened, principal investigator must submit a SAE report to REC within 24 hours and follow up within 7 days. All AEs and SAEs will be reported to REC in the annual progress report and in the final study report. IV) Compliance and dropout: For maximizing participants' compliances, first, the investigators have a thorough consent process for all participants by explaining the details of the study schedule, potential side effects of treatment, the responsibilities the participants needed to take and together with the support and reassurance during the whole study. Second, the investigators have a careful scrutiny (2-week run-in period) to exclude ineligible and low compliance participants before randomization. Third, a special e-mail account and a direct telephone hotline equipping with this clinical trial are ways for the study team to actively communicate with participants and reply enquiries. Moreover, extra-visits will be arranged for participants to see WM doctor or TCM practitioner if participants develop adverse events before the next scheduled visit. If any patient has thoughts of withdrawing or dropping out, he/she will try to determine the reason. The investigators would try to find solution in order to keep the patient in the study. V) Data collection and management: Case report forms (CRFs) will be filled in by investigators. Collectable information includes patient identification and demographic data, clinical history, dietary history, personal history, family history, substance use, IBS medical history and clinical examination. Data processing will be conducted in accordance with the following protocol: 1. Verification of CRFs: Investigators need to verify CRFs before inputting. 2. Data verification needs to be conducted successively in the following two steps: 1. Verify the consistency and logicality of data: Review contents of data range and logicality will be determined by the range of each index and the interrelation. Corresponding software formula will also be applied to assist the data input. 2. Compare database and CRFs by manual testing. Selectively counter check 10% CRFs with participants' medical notes to check the quality of input and analyze. 3. Data inspection and closure of database: After verifying the validity of established database and statistical protocol, principal investigators will lock the data. The locked data are not allowed to change. Confirmed problems found after locking will be handled in the process of statistical analysis. All mistakes and modification should be recorded and kept properly. Investigators should keep all trial materials, including acknowledgement of all participants, original informed consent forms with participant's signature, all CRFs and detailed record of medications distribution, which should be provided to ethics committee and drug supervision and administration department for reviewing. All files will be maintained in storage for a period of 7 years after the completion of the clinical trial. Data access during study will be restricted except investigators, ethics committee, and government authority. After the study, all the data will be deidentified and available for sharing upon reasonable request. VI) Sample size calculation: The study is the first sham-controlled acupuncture trial that uses the Food and Drug Administration (FDA) recommended end point for IBS-C. The sample size was determined based on the study's purpose, statistical precision, feasibility, and reported improvements in clinical symptoms (abdominal pain, bloating, feeling of incomplete defecation, stool frequency, stool shape) from previous acupuncture studies on IBS-C patients. With an alpha of 0.05, a power of 0.8, a 20% dropout rate, and the potential for missing data, a total sample size of 60 patients (30 in experimental arm and 30 in control arm) is required. VII) Statistical analysis: All efficacy and safety analyses will be conducted based on intention-to-treat (ITT) principle. Missing values will be imputed by the last-observation-carried-forward method. The statistical analysis will be performed using the Stata software. The statistical significance will be defined as two-sided P-value of \<0.05. Baseline characteristics will be reported as mean (SD). Baseline differences between the groups will be evaluated with the application of Student's t-test for normally distributed continuous variables and non-parametric Mann-Whitney U test for non-normally distributed variables. For categorical variables, chi-squared test or Fisher's exact test will be applied. Comparisons between groups will be conducted by using unpaired t-test for normally distributed data and Mann-Whitney test for non-normally distributed data. Within group differences will be evaluated with paired t-test for normally distributed data and Wilcoxon signed-rank test for non-normally distributed data.

主要结局

次要结局

• Median time to the first spontaneous bowel movements, complete spontaneous bowel movements after electro-acupuncture(From first session of electro-acupuncture up to the end of follow-up, approximately 12 weeks)
• Average number of bisacodyl tablets or enemas used per week(Baseline, week 8, week 14)
• Global assessment of efficacy of treatment with Likert scale(Week 5, week 8, week 14)
• Proportion of patients with an improvement of ≥30% in abdominal pain scores(Baseline, week 8, week 14)
• Proportion of patients with an average increase of 1 or more spontaneous, complete bowel movements per week(Baseline, week 8, week 14)
• Average number of spontaneous bowel movements, complete spontaneous bowel movements per week(Baseline, week 8, week 14)
• Percentage of bowel movements with normal consistency(Baseline, week 8, week 14)
• Percentage of bowel movements with severe or very severe straining during defecation(Baseline, week 8, week 14)
• Change from baseline in the IBS-C symtoms using IBS Symptom Severity Scale (IBS-SSS)(Baseline, week 5, week 8, week 14)
• Change from baseline in the IBS-C symtoms using IBS Quality of Life (IBS-QOL)(Baseline, week 5, week 8, week 14)
• Change from baseline in the IBS-C symtoms using Patient Assessment of Constipation Symptoms (PAC-SYM)(Baseline, week 5, week 8, week 14)
• Change from baseline in the IBS-C symtoms using Constipation Quality of Life (PAC-QOL)(Baseline, week 5, week 8, week 14)
• Change from baseline in the IBS-C symtoms using Patient Health Questionnaire-15 (PHQ-15)(Baseline, week 5, week 8, week 14)
• Change from baseline in the psychological conditions using Hamilton Depression Scale (HAMD)(Baseline, week 8, week 14)
• Change from baseline in the psychological conditions using Self-rating Depression Scale (SDS)(Baseline, week 8, week 14)
• Change from baseline in the psychological conditions using Patient Health Questionnaire (PHQ-9)(Baseline, week 8, week 14)
• Change from baseline in the psychological conditions using General Anxiety Disorder (GAD-7)(Baseline, week 8, week 14)
• Change from baseline in the psychological conditions using Hospital Anxiety and Depression Scale (HADS)(Baseline, week 8, week 14)
• Change from baseline in the psychological conditions using Visceral Sensitivity Index (VSI)(Baseline, week 8, week 14)
• Change from baseline in the psychological conditions using Perceived Stress Scale (PSS)(Baseline, week 8, week 14)
• Patient expectancy and trust in treatment with Likert scale(Week 2, week8, week 14)
• Recruitment rate(Baseline)
• Retention rate(Baseline to week 14)
• Adherence to treatment protocols(Baseline to week 14)
• Completeness and quality of symptom diaries and questionnaire responses(Baseline, week 5, week 8, week 14)
• Number and type of adverse events documented(Baseline to week 14)